The aim of this population-based cohort study was to investigate whether the magnitude of potential benefit of AIs compared to TAM as adjuvant therapy in postmenopausal BC patients was different based on HER2-status in the modern era of HER2-directed therapy. The gene discussed is ERBB2; the disease is breast cancer.